Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based developer of a blood test for the early detection of a majority of the different forms of lung cancer, announces that at the General Meeting (“GM”) of the Company being held later today, Allan Syms, Executive Chairman, will make the following statement:
“Since the admission to trading of Cizzle Biotechnology on the London Stock Exchange in May I am pleased to report that we have already made significant progress with the development of our prototype CIZ1B biomarker test for the early detection of lung cancer, in line with the strategy outlined in the prospectus published in conjunction with admission.
“In addition to the work currently being undertaken at the University of York, we have now selected manufacturers and contract research organisations (“CROs”) to conduct the required reagent generation, test manufacture and clinical validation to achieve CE marking and/or FDA 510(k) clearance for the test. I am pleased to say that we are working with CROs that have proven track records of delivering robust and reliable reagents (together with monoclonal antibodies) for existing global pharmaceutical industry clients and I am confident that we will enter into definitive formal contractual arrangements with them as required.
“I am also pleased to report that we have commenced a robust health economics exercise to establish that the test satisfies the specific economic requirements and benefits required by the NHS and its patients. We are also investigating additional global strategic alliances in order to facilitate the future commercial acceptance and roll-out of the test worldwide.”
